FDA Authorizes Pfizer-BioNTech Vaccine for Emergency Use in Adolescents

May 11, 2021 by Alexa Hornbeck
FDA Authorizes Pfizer-BioNTech Vaccine for Emergency Use in Adolescents
This Jan. 24, 2021, photo shows a vial of the Pfizer vaccine for COVID-19 in Seattle. (AP Photo/Ted S. Warren, File)

WASHINGTON – The U.S. Food and Drug Administration announced Monday the Pfizer-BioNTech vaccine has been approved for emergency use for adolescents ages 12 to 15 years of age. 

“Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations,” said Acting FDA Commissioner Janet Woodcock, M.D. 

The FDA has determined that Pfizer-BioNTech COVID-19 vaccine has met the statutory criteria to amend the emergency use authorization, and that the known and potential benefits of this vaccine in individuals 12 years of age and older outweigh the known and potential risks, supporting the vaccine’s use in this population. 

The emergency use authorization will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biologics for prevention and treatment of COVID-19 is terminated and may be revised or revoked if it is determined the emergency use authorization no longer meets the statutory criteria for issuance or to protect public health or safety. 


The available safety data to support the emergency use authorization in adolescents down to 12 years of age, includes 2,260 participants ages 12 through 15 years old enrolled in an ongoing randomized, placebo-controlled clinical trial in the U.S. Of these, 1,131 adolescent participants received the vaccine and 1,129 received a saline placebo. More than half of the participants were followed for safety for at least two months following the second dose. 

The immune response of adolescents was at least as good as the immune response of the older participants. An analysis of cases of COVID-19 occurring among participants, 12 through 15 years of age, seven days after the second dose was also conducted. 

The vaccine was 100% effective in preventing COVID-19, as participants without evidence of prior infection with SARS-CoV-2, no cases of COVID-19 occurred among 1,005 vaccine recipients and 16 cases of COVID-19 occurred among 978 placebo recipients. 


From March 1, 2020, through April 30, 2021, approximately 1.5 million COVID-19 cases in individuals 11 to 17 years of age have been reported to the Centers for Disease Control and Prevention.  

Children and adolescents generally have a milder COVID-19 disease course as compared to adults. 

“Having a vaccine authorized for a younger population is a critical step in continuing to lessen the immense public health burden caused by the COVID-19 pandemic,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. 

The FDA has updated the Fact Sheets for Healthcare Providers Administering the Vaccine (Vaccination Providers)  and for Recipients and Caregivers with information to reflect the use of the vaccine in the adolescent population, including the benefits and risks of the Pfizer-BioNTech COVID-19 Vaccine. 

The most commonly reported side effects in the adolescent clinical trial participants, which typically lasted 1-3 days, were pain at the injection site, tiredness, headache, chills, muscle pain, fever and joint pain.  

With the exception of pain at the injection site, more adolescents reported these side effects after the second dose than after the first dose, so it is important for vaccination providers and recipients to expect that there may be some side effects after either dose, but even more so after the second dose.  


The side effects in adolescents were consistent with those reported in clinical trial participants 16 years of age and older. It is important to note that as a general matter, while some individuals experience side effects following any vaccination, not every individual’s experience will be the same and some people may not experience side effects. 

Since its authorization for emergency use, rare severe allergic reactions, including anaphylaxis, have been reported following administration of the Pfizer-BioNTech COVID-19 vaccine in some recipients, as such the vaccine should not be given to anyone with known history of severe allergic reaction, including anaphylaxis. 

A+
a-

In The News

Health

Voting

Health

Arizona Clinic Has Workaround for Abortion Pill Ban

PHOENIX (AP) — A Phoenix abortion clinic has come up with a way for patients who can end their pregnancy... Read More

PHOENIX (AP) — A Phoenix abortion clinic has come up with a way for patients who can end their pregnancy using a pill to get the medication quickly without running afoul of a resurrected Arizona law that bans most abortions. Under the arrangement that began Monday,... Read More

Kids With Disabilities Face Off-the-Books School Suspensions

The phone call from her son’s school was alarming. The assistant principal told her to come to the school immediately.... Read More

The phone call from her son’s school was alarming. The assistant principal told her to come to the school immediately. But when Lisa Manwell arrived at Pioneer Middle School in Plymouth, Michigan, her son wasn’t sick or injured. He was sitting calmly in the principal’s office.... Read More

October 3, 2022
by Dan McCue
9/11-Related Illness Deaths for FDNY Will Soon Surpass Deaths on Day of Attack

NEW YORK — Within the next year, the number of members of the New York City Fire Department who will... Read More

NEW YORK — Within the next year, the number of members of the New York City Fire Department who will have died from a 9/11-related illness will surpass the number of fire fighters and emergency medical technicians who died in the terror attack 21 years ago.... Read More

UnitedHealth Closes Roughly $8B Deal for Change Healthcare

MINNETONKA, Minn. (AP) — UnitedHealth Group said Monday that it completed its acquisition of Change Healthcare, closing the roughly $8... Read More

MINNETONKA, Minn. (AP) — UnitedHealth Group said Monday that it completed its acquisition of Change Healthcare, closing the roughly $8 billion deal a couple weeks after a judge rejected a challenge from federal regulators. UnitedHealth is merging the technology company with its Optum segment. The health... Read More

It's Flu Vaccine Time and Seniors Need Revved-Up Shots

Doctors have a message for vaccine-weary Americans: Don’t skip your flu shot this fall — and seniors, ask for a special... Read More

Doctors have a message for vaccine-weary Americans: Don’t skip your flu shot this fall — and seniors, ask for a special extra-strength kind. After flu hit historically low levels during the COVID-19 pandemic, it may be poised for a comeback. The main clue: A nasty flu season just ended in... Read More

September 30, 2022
by Dan McCue
HHS Rolls Out First-Ever Diaper Distribution Program

WASHINGTON — Families in need in six states and one tribal territory will be the beneficiaries of a new diaper... Read More

WASHINGTON — Families in need in six states and one tribal territory will be the beneficiaries of a new diaper distribution program rolled out by the Department of Health and Human Services this week. The pilot program will award $8 million in funding to community service... Read More

News From The Well
scroll top